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The P2X7 receptor is an adenosine triphosphate (ATP)-gated cation channel that is
expressed by several cells of the immune system. P2X7 is best known for its proinflamma-
tory role in promoting inflammasome formation and release of mature interleukin (IL)-1β
by innate immune cells. Mounting evidence indicates that P2X7 is also an important
regulatory receptor of murine and human T cell functions. Murine T cells express a
sensitive splice variant of P2X7 that can be activated either by non-covalent binding of ATP
or, in the presence of nicotinamide adenine dinucleotide, by its covalent ADP-ribosylation
catalyzed by the ecto-ADP-ribosyltransferase ARTC2.2. Prolonged activation of P2X7 by
either one of these pathways triggers the induction of T cell death. Conversely, lower
concentrations of ATP can activate P2X7 to enhance T cell proliferation and production
of IL-2. In this review, we will highlight the molecular and cellular consequences of P2X7
activation on mouse T cells and its versatile role in T cell homeostasis and activation.
Further, we will discuss important differences in the function of P2X7 on human and
murine T cells.
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Mechanisms Leading to Activation of P2X7 by Extracellular ATP
or NAD+ on Mouse T Cells
The family of ionotropic P2X receptors comprises seven members that are able to form trimeric
ion channels reactive to extracellular adenosine triphosphate (ATP). In the context of the immune
system, P2X7 is best known for its role in promoting inflammasome formation and release of
the proinflammatory interleukin 1β (IL-1β) from innate immune cells such as macrophages and
monocytes after exposure to lipopolysaccharide and ATP (1). Further, P2X7 has also been identified
as an important regulator of mouse T cell functions. P2X7 triggered by extracellular ATP induces
the formation of a non-selective cation channel, resulting in the influx of calcium and sodium ions
as well as the efflux of potassium. Interestingly, P2X7 can also be triggered via an ATP-independent
pathway that has been discovered and characterized on mouse T cells. The mechanism involves the
ecto-ADP-ribosyltransferase ARTC2.2 which, in the presence of its substrate nicotinamide adenine
dinucleotide (NAD+), catalyzes the ARTC2.2-dependent ADP-ribosylation of P2X7 at an arginine
residue at position 125 at the edge of the ATP-binding pocket in the extracellular domain of the
protein (Figure 1A) (2, 3). This covalent posttranslational modification occurs even at 4°C, however
gating of P2X7 is triggered only at 37°C. Since NAD+ is released during cell preparation, alterations
of T cell phenotype and function due to NAD+-dependent ADP-ribosylation of P2X7 can easily be
evidenced on freshly harvested T cells extracted from lymphoid organs following their re-incubation
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FIGURE 1 | Cellular consequences of P2X7 activation on mouse
T cells. (A) Non-covalent binding of ATP or covalent ARTC2.2-mediated
ADP-ribosylation results in P2X7 channel gating and in the influx of calcium
and sodium ions and the efflux of potassium. (B) P2X7 activation triggers the
activation of ADAM10 and ADAM17 that catalyze the shedding of the
ectodomains of various cell surface proteins such as CD27, CD62L and
IL-6R. (C) P2X7 activation leads to phosphatidylserine (PS) externalization,
formation of a non-selective membrane pore allowing the uptake of
fluorescent molecules such as DNA staining dyes, and ultimately to cell death.
at 37°C (4–6). Importantly, NAD+-dependent activation of P2X7
can only be observed with mouse T cells but not with human T
cells that lack ADP-ribosyltransferase activity due to premature
stop codons in the orthologous pseudogene (7).
Interestingly, NAD+-dependent activation of P2X7 by ADP-
ribosylation provides a long-lasting activation signal, even after
a brief exposition to relatively low concentrations of extracellular
NAD+ (i.e., 1–30 µM) (8). In contrast, P2X7 activation by the
non-covalent binding of ATP necessitates its continuous presence
in the extracellular milieu at sufficient concentrations (i.e., above
100 µM) (4). It is therefore suspected that regulation of T cell phe-
notype, function, survival, and differentiation by either of these
pathways occurs in different pathophysiological situations that are
not necessarily redundant. Both activation pathways are tightly
regulated by ectoenzymes, notably by the ATP-degrading ectonu-
cleoside triphosphate diphosphohydrolase CD39 and the NAD+-
degrading ecto-NAD+-glycohydrolaseCD38, respectively (9–11).
Of note, these enzymes have been demonstrated to participate
in the regulation of immune responses and T cell activation
and function. For instance, CD39 has been implicated in the
suppressive functions of regulatory T cells (Tregs) and CD38
in the activation of human T cells via the generation of cyclic
ADP-ribose (cADPR) that can cause the release of Ca2+ from
intracellular ryanodine-sensitive stores (12, 13). Additionally, the
activity of these enzymes participates in the maintenance of low
extracellular ATP or NAD+ concentrations in biological fluids.
Under steady-state conditions, their concentrations in the serum
have been estimated in the submicromolar range (14, 15). There-
fore, activation of P2X7 by ATP or NAD+ is limited to situations
where intracellular pools of nucleotides are released in substantial
amounts. Interestingly, ATP has been demonstrated to be released
in the tumor microenvironment in concentrations that are fully
compatible with the in vivo direct activation of P2X7 at the surface
of innate immune cells and tumor-infiltrating T cells (16, 17).
Whether NAD+ can also be released in this situation is presently
not known, but NAD+ has been demonstrated to be released
within inflammatory sites and to affect the phenotype and survival
of T cells located in the proximal draining lymph nodes via the
ARTC2.2/P2X7 pathway (18).
Molecular and Cellular Consequences of
P2X7 Activation on Mouse T Cells
Activation of P2X7 on T cells by extracellular ATP or following
NAD+-dependent ADP-ribosylation induces changes in cell vol-
ume and composition of the plasma membrane. T cells respond
to ATP stimulation with rapid sequential shrinkage and swelling
and externalization of phosphatidylserine (PS) onto the outer
leaflet of the plasma membrane (Figure 1C) (19, 20). Analyses of
thymocytes revealed that PS externalization is related to the influx
of both, calcium and sodium ions, inhibiting aminophospholipid
translocases responsible for maintaining PS at the inner leaflet of
the plasmamembrane, and simultaneously activating scramblases
which catalyze the bidirectional transbilayermovement of PS (21–
23). Externalization of PS is regarded as an early indicator of
the induction of apoptosis. Prolonged activation of P2X7 indeed
triggers T cell death which can be visualized by staining with
DNA-binding dyes such as propidium iodide following loss of
membrane integrity (4). Interestingly, PS exposure after ATP
stimulation is reversible if the ATP is removed within the first
30min of exposure (24). Conversely, PS exposure following ADP-
ribosylation of P2X7 is not reversed by removing the ARTC2
substrate NAD+ (2).
Another hallmark of P2X7 activation is the formation of mem-
brane pores permeable to molecules up to a molecular weight of
900Da. Pore formation has been functionally linked to the long
intracellular C-terminus region of P2X7 (25). However, whether
P2X7 itself directly mediates pore formation by channel dilation
or whether other P2X7-associated proteins such as pannexin 1
form the pores is still a matter of debate. Interestingly, inhibition
of pannexin-1 significantly reduced ATP-induced mouse T cell
death (26). This suggests that drastic elevation of intracellular
Ca2+, either through P2X7 itself or via other associated non-
selective pore-forming proteins, may represent an essential com-
mon event triggered in the early phase leading to cell death. A
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recently published study identified the phospholipid scramblase
anoctamin 6 (ANO6), another non-selective cation channel, as
a new key player in the formation of membrane pores following
P2X7 activation on macrophages (27). Whether ANO6 is also
involved in P2X7-mediated pore formation in T cells needs to be
further investigated.
P2X7 activation is associated with a rapid change in T cell
surface phenotype. The mechanism involves the activation of the
membrane-associated metalloproteases ADAM10 and ADAM17
that catalyze the shedding of the ectodomains of various cell
surface proteins such as CD62L (28), CD27 (29), and IL-6R (30)
(Figure 1B). Hence, on the cellular level, activation of P2X7 on T
cells results in the triggering of multiple signaling pathways that
affect cell morphology, phenotype, and viability. In the following
sections, we will discuss the impact of P2X7-mediated cell death
on T cell function and homeostasis.
Allelic and Splice Variants Affect the
Functionality of P2X7
In the mouse, single nucleotide polymorphisms (SNP) and alter-
native splicing result in the expression of different P2X7 variants
(1, 31–35). An allelic variant of P2X7 located in the long C-
terminal cytosolic tail was discovered in widely used C57BL/6
laboratory mice. The 451L variant found in this strain affects
the function of the receptor when expressed by HEK cells as
compared to the P451 P2X7 allelic variant found in the BALB/c
strain. Side-by-side comparison of T cells from both strains
concordantly showed impaired functional responses of the 451L
variant to P2X7 stimulation leading to the conclusion that the
P451L SNP affects the functionality of P2X7 expressed by con-
ventional mouse T cells (36). However, later analyses using anti-
P2X7 antibodies suitable for flow cytometry analysis demon-
strated that conventional T cells from C57BL/6 display very low
cell surface expression of P2X7 which possibly accounts for their
relative insensitivity to P2X7 ligands (5). The situation was fur-
ther complicated by the discovery of two alternatively spliced
variants termed P2X7a and P2X7k with different sensitivity to
P2X7 agonists. Structurally, the P2X7k variant differs from the
previously described P2X7a by 42 amino acids encompassing the
N-terminal cytosolic region and a part of the first transmembrane
domain (25). Functionally, the P2X7k variant was found to be
8–10 times more sensitive to P2X7 agonists than the classical
P2X7a variant (37). Also, we and others have shown that P2X7k
is the predominant variant expressed by T cells, whereas P2X7a
is the predominant variant expressed by macrophages (38, 39).
Interestingly, differential expression of these variants on immune
cells explains earlier observed differences in the sensitivities of
T cells and macrophages to extracellular ATP (40). Additionally,
expression of both variants in HEK cells revealed that only the
P2X7k variant can be efficiently activated by ADP-ribosylation
even though both variants are equally modified by ARTC2.2 in
the presence of extracellular NAD+ (38, 39). This was attributed
to a higher stability of the activated state of this variant compared
with P2X7a. Further, these studies also demonstrated that the
P451L SNP described earlier only impairs the functionality of
P2X7a but not the functionality of the highly sensitive P2X7k
variants. Hence, lower sensitivity of conventional T cells from
C57BL/6 mice to ATP and NAD+ most likely reflects lower
cell surface expression of P2X7k rather than impaired function-
ality due to the 451L SNP that would rather affect cells like
macrophages and dendritic cells (DCs) that express the P2X7a
splice variants.
Unexpectedly, the characterization of mouse P2X7k splice vari-
ants brought new insights to some apparently conflicting results
using P2X7-deficientmice. Two distinct P2X7-deficient lines have
been generated and were used to decipher the function of P2X7
in vivo. One P2X7-deficient mouse, developed by Pfizer, was gen-
erated by disrupting the last exon coding for the long C–terminal
cytoplasmic tail (41). In the other P2X7-deficient mouse, gen-
erated by GlaxoSmithKline (GSK), the lacZ gene was inserted
at the beginning of exon 1 (42–44). However, two independent
studies revealed that the latter mice do express a functional P2X7
receptor on T cells, whereas DCs, macrophages, and neurons were
effectively deficient in P2X7 functional activity (37, 45). Later
studies revealed that this is due to the preferential use of the
P2X7k variant in T cells which escapes exon 1 targeted disruption
(i.e., using an alternative exon 10) in the GSK knockout strain
(37, 38). This finding may be important for our understanding
of the role of this receptor in vivo and may help reinterpret some
contradictory results. For instance, autoimmune encephalomyeli-
tis was found to be exacerbated in the Pfizer knockout strain,
whereas it was found to be attenuated in GSK knockout strain
(46, 47). Future studies using tissue-specific P2X7 disruption in
lymphoid, myeloid, or oligodendrocytes cells should help clarify
this issue.
P2X7 Expression on T Cells of Different
Differentiation and Maturation Stages
P2X7 expression on mouse T cells depends on differentiation
and maturation stage. Cell death can be induced in a fraction
of thymocytes by extracellular ATP suggesting that P2rx7 gene
expression is induced in T cells during their differentiation in
the thymus (48). The precise physiological role of P2X7 on the
selection of the T cell repertoire is not known but ATP has been
suggested to play a role in thymocyte death by neglect and in the
thymic differentiation of γδ T cells (49). Our own early studies
have revealed that single positive CD4+ or CD8+ thymocytes
express higher levels of surface P2X7 than less differentiated dou-
ble positive cells suggesting that P2X7 expression correlates with T
cell maturation. Accordingly, peripheral T cells displayed higher
sensitivity to ATP andNAD+ than thymocytes (2, 50). Onmature
peripheral T cells, CD4+ T cells display slightly higher surface
levels of P2X7 as compared to CD8+ T cells that may account in
part for their higher sensitivity to extracellular ATP and NAD+.
Interestingly, P2X7 surface expression also seems to be regulated
by activation. Indeed, cells expressing T cell activation markers
display lower P2X7 levels than their naive counterparts (18). Also,
recently activated T cells display a lower level of ARTC2.2 possibly
as a result of its shedding from the cell surface bymetalloproteases
(51). Of note, the relative expression levels of P2X7a and P2X7k
variants during cell differentiation in the thymus, inmatureCD4+
or CD8+ T cell lineages, or after activation are currently not
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known but may possibly regulate the sensitivity to extracellular
ATP and NAD+.
P2X7-Mediated Cell Death Affects the
Quality of Ex Vivo Murine T Cell
Preparations
Several studies have shown that the expression levels of P2X7
and ARTC2.2 differ among T cell subsets (52, 53). Tregs and
liver natural killer T cells (NKTs) exhibit a higher cell surface
expression of P2X7 as compared to conventional naïve CD4+
T cells, and this is associated with a higher sensitivity to ATP-
and NAD+-mediated cell death (5, 6, 54, 55). High sensitivity to
extracellular NAD+ negatively correlates with the survival and
function of ex vivo freshly prepared Tregs and liver NKTs. This
has a significant impact on in vitro assays and on adoptive transfer
experiments (6). NAD+ is released in sufficient amounts during
organ collection and cell preparation to ADP-ribosylate P2X7 on
a large fraction of Tregs and on the majority of liver NKTs even
when cells are prepared on ice. This leads to the induction of
P2X7-mediated cell death when the cells are returned to 37°C
either in vitro or after their adoptive transfer into living animals
(Figure 2). To overcome this detrimental effect, an ARTC2.2-
antagonizing nanobody (clone s+ 16a) has been developed (56)
and was shown to prevent ADP-ribosylation-related detrimental
effects induced during ex vivo cell preparation when injected a
fewminutes before sacrificing the mice (Figure 2). This markedly
preserved the viability, the phenotype and the function of har-
vested Tregs and NKTs and improved subsequent downstream
applications in vitro and in vivo (6).
P2X7-Mediated Cell Death Regulates
Mouse T Cell Homeostasis In vivo
P2X7-dependent cell death plays an important role in the home-
ostatic regulation of diverse T cell populations during steady state
and in pathophysiological contexts. The endogenous sources of
extracellular ATP andNAD+ remain an important questionwhen
addressing the role of P2X7 in vivo. Obviously, ATP and NAD+
can be passively liberated from damaged cells in traumatic situa-
tions (4). However, extracellular nucleotides can also be liberated
from living cells in various situations (e.g., during cell activation,
during autophagy, in conditions of shear-force stress, oxidative
stress, or from transformed cells) through hemichannels such
as pannexin 1 or connexin 43 and possibly through other still
unknown mechanisms (57, 58). In a proof-of-principle study,
we previously showed that NAD+ is released at inflammatory
sites and even can gain access to the local draining lymph nodes
(18). This led to P2X7-dependent phenotypic changes and to the
depletion of a fraction of naïve T cells that were detectable in
wildtype (WT) mice and, more prominently, in CD38-deficient
mice, in which NAD+ has a longer half-life in the extracellular
compartment.
Given the higher sensitivity of Tregs and NKTs to ATP- and
NAD+-mediated cell death, the role of P2X7 in their homeostatic
maintenance in vivo was studied (5, 6, 54, 55). P2X7 negatively
regulates the number of peripheral Tregs and was therefore sug-
gested to participate in their homeostasis. Indeed, P2X7-deficient
mice exhibit higher numbers of Tregs in the spleen compared to
their WT counterparts. Conversely, CD38-deficient mice display
lower numbers of Tregs in the spleen, indirectly suggesting that
FIGURE 2 | P2X7-dependent alteration of T cells can be prevented by
blocking the activity of ARTC2.2. Freshly prepared spleen CD4+Foxp3+
Tregs and liver CD3+CD1d-tetramer+ NKT cells remain unaffected when kept
at 4°C but rapidly shed CD27 when re-incubated at 37°C due to NAD+ release
during cell preparation and ARTC2.2-mediated ADP-ribosylation of P2X7 (left
panel). These cells also rapidly shed CD62L and expose phosphatidylserine at
their cell surface (not illustrated here). Intravenous injection of an anti-ARTC2.2
blocking nanobody (s+ 16a) before harvesting of the organs prevents
ADP-ribosylation of P2X7 during cell manipulation and P2X7-dependent CD27
shedding when cells are re-incubated at 37°C (right panel).
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extracellular NAD+ also regulates Treg homeostasis (5). Whether
the increased number of Tregs in P2X7-deficient mice is related
to ATP- and/or NAD+-induced cell death needs to be further
investigated. Interestingly, CD38 deficiency similarly affects the
number ofNKTs. Thiswas observed in diabetes-proneNODmice,
in which CD38 deficiency was accompanied by an accelerated
onset of diabetes (59).We could further show that in vivo blockade
of the ARTC2.2/P2X7 pathway using an ARTC2.2-antagonistic
nanobody restored normal numbers of NKT cells in these mice
suggesting that extracellular NAD+ indeed can influence NKT
cell homeostasis (59).
The high sensitivity of Tregs and NKTs to NAD+-induced
P2X7-dependent cell death has been exploited to deplete these
cells in vivo. Injection of NAD+ into mice depleted NKT cells
and protected mice from concanavalin A (ConA)-mediated
autoimmune hepatitis. This was linked to a transient decrease in
the number of liver NKT cells, which otherwise respond to ConA
with amassive production of proinflammatory cytokines resulting
in severe liver damage (55, 60). Similarly, a single intravenous
injection of NAD+ decreased the number of peripheral Tregs
by 80%. When applied 24 h before tumor engraftment, this
unleashed an effective anti-tumor immune response leading to
tumor rejection (5).
The role of P2X7 in the tumor microenvironment has been
investigated in two recent publications addressing tumor pro-
motion and tumor growth in P2X7-deficient mice. In one of
these studies, genetic and pharmacological inactivation of P2X7
was demonstrated to increase tumor development in a model
of colitis-associated cancer (61). Interestingly, this was associ-
ated with alteration of the number and the quality of tumor-
infiltrating immune cells and, notably, by the accumulation of
Tregs within the colonic lesions. Their accumulation in the tumor
of P2X7-deficient is compatible with their high sensitivity to
P2X7-dependent cell death that would partially prevent their
early accumulation within the tumor microenvironment of WT
mice. However, only naive Tregs, but not activated Tregs that
are resistant to P2X7-dependent cell death, would be affected by
such amechanism.Anothermechanism could additionally rely on
the more efficient priming of anti-tumor CD8+ T cell response
in WT mice through a P2X7/NLRP3-dependent maturation of
DCs and effective tumor-antigen presentation to the adaptive
immune system that could also influence the effector/Tregs ratio
found within the tumors (62). This is supported by the finding
of the second study showing accelerated tumor progression in
P2X7-deficient hostmice inoculated with B16melanoma or CT26
colon carcinoma cell lines (63). In this study, DCs from P2X7-
deficient host mice were found to be unresponsive to stimulation
with tumor cells in vitro which correlates in vivo with a lower
intratumoral level of IL-1β and a lower infiltration by immune
cells and notably by CD8+ cytotoxic T cells. Collectively, these
studies highlights the importance of P2X7 expression onTregs and
DCs in the anti-tumor immune response and in the restriction of
tumor growth.
Interestingly, intestinal CD8+ T cells (both conventional
CD8αβ+ as well as unconventional CD8αα+ T cells) express
higher levels of surface P2X7 as compared to splenic CD8+ T cells
(64). Accordingly, intestinal CD8+ T cells are more susceptible to
ATP- and NAD+-induced cell death in vitro. Similarly, injection
of NAD+ leads to a depletion of these cells in vivo. These data
suggested for the first time that P2X7 expression level is not only
regulated during T cell differentiation but also by tissue-derived
specific factors. For intestinal CD8+ Tcells, intestinal retinoic acid
(RA) was suggested to contribute to P2X7 and ARTC2.2 upregu-
lation (64). Indeed, DCs located in the gut-associated mesenteric
lymph nodes and Peyers Patches (PPs) express retinal dehydro-
genase and generate retinoic acid from orally derived vitamin A
(65, 66). Accordingly, incubation of splenic CD8+ T cells with RA
significantly upregulated the surface levels of P2X7 and ARTC2.2.
A functional implication of the higher P2X7 expression on intesti-
nal CD8+ cells was studied in the context of intestinal Listeria
monocytogenes (LM) infection. P2X7-deficient mice infected with
LM exhibit higher frequencies of antigen-specific IFNγ+ CD8+ T
cells in the intestinal epithelium compared to infected WT mice.
Whether this is related to enhanced survival of intestinal CD8+ T
cells to ATP and/or NAD+ derived from the inflammatory site or
to other mechanisms needs to be further investigated (64).
Importantly, recent work by the group of Fabio Grassi high-
lighted the role of P2X7 in regulating the survival of T follicular
helper cells (Tfh) in the gut environment (67). Tfh cells in the
PPs promote the secretion of high-affinity IgA, which affects
intestinal homeostasis, mucosal defense, and the composition of
intestinal microbiota. P2X7 is expressed at high levels on Tfh
located in PPs and critically regulates their survival and/or func-
tion. Indeed, under steady-state conditions, P2X7-deficient mice
displayed increased numbers of Tfh and germinal centers in their
PPs along with an enhanced production of high-affinity IgA,
which resulted in an alteration of the microbiota. Consequently,
P2X7-deficient mice exhibited lower serum IgM concentrations
and increased susceptibility to polymicrobial sepsis (67).Whether
P2X7-dependent control of Tfh homeostasis in PPs is regulated
by local release of ATP and/or NAD+ and how this might be
amplified during intestinal inflammation needs to be further
investigated.
In summary, current data suggest that P2X7-mediated cell
death constitutes a crucial factor for the homeostatic regulation of
several T cell subsets that play essential roles in the regulation of
immune responses. P2X7 can therefore be viewed as an important
regulator of T cell functions, notably through the induction of
P2X7-dependent T cell death. Still, dependent on the level of
expression of P2X7 and on the amount of available extracellu-
lar ATP and/or NAD+, P2X7 may also conceivably regulate T
cell activation and/or function without necessarily inducing cell
death. In the following section, we will highlight the role of P2X7
as a co-stimulatory partner during the activation of T cells.
P2X7-Mediated Autocrine Stimulation of
Human and Mouse T Cells
It has become clear that ATP can be released from living cells
in different physiological and pathophysiological situations (68).
For instance, hypertonic and mechanical stress induces defor-
mation of the plasma membrane that can lead to the lib-
eration of ATP into the extracellular milieu from many cell
types. When applied to Jurkat T cells, hypertonic stress leads
to the rapid release of extracellular ATP, to the augmenta-
tion of intracellular Ca2+, to mitogen-activated protein kinase
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(MAPK) activation, and to enhanced expression of interleukin
2 (IL-2) (69). Studies addressing the underlying mechanisms of
ATP release identified pannexin 1 hemichannels as a critical
mediator of ATP release in response to hypertonic stress (70).
Interestingly, TCR stimulation by itself triggered the release of
ATP in a pannexin-1 dependent manner (71, 72). ATP released
FIGURE 3 |Modulation of human T cells phenotype, response to
mitogenic stimulation, and survival by ATP and P2X7. P2X7-stimulation on
the surface of human T cell may have different consequences which could
hypothetically depend on the extracellular concentration of ATP, P2X7 density,
expression of CD39 and other ATPases, on the nature of T cell subsets, and on
their activation status. (A) High concentration of extracellular ATP have been
reported to culminate, at least in vitro, in the induction of cell death possibly
through the induction of massive membrane depolarization and
permeabilization. (B) At lower ATP concentration and/or if cells express a low
level of surface P2X7 and/or a high level of ATP-catabolizing enzymes,
P2X7-activation could participate instead in T cell costimulation by enhancing
the intracellular level of Ca2+, an universal second messenger (76, 78). This may
result in the stimulation of NFAT, MAPKs, and IL-2 secretion (69, 70, 72), and in
the activation of metalloproteases that catalyze the shedding of CD62L and of
other cell surface proteins (79). (C) In some studies, TCR stimulation by
mitogenic activators was shown to promote ATP release through pannexin 1
favoring autocrine/paracrine T cell co-stimulation (69, 70, 72). (D) TCR
stimulation was also found to stimulate the translocation of pannexin 1 at the
immunological synapse together with P2X1 and P2X4 (80). P2X7 is also found
within the immunological synapse even if it is not actively translocated within the
immunological synapse and remains instead uniformly distributed across the cell
surface. This mechanism may thus serve to provide a tonic co-stimulatory signal
during physiological activation of a T cell in contact with antigen-presenting cells
by promoting the local release of ATP within the immunological synapse, and
the local activation of P2X receptors expressed by T cell as well as by
antigen-presenting cells.
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during TCR stimulation activates P2X7, which sustains MAPK
signaling, stimulating IL-2 expression and enhancing T cell pro-
liferation. Further, antagonism of P2X7 during TCR activation
blunted MAPK signaling and induced a transcriptional program
characteristic for T cell anergy (71). The importance of this
regulatory mechanism has been evaluated in a mouse model of
diabetes that is based on the adoptive transfer of hemagglutinin
(HA)-specific TCR-transgenic T cells into Rag2-/- mice express-
ing HA under control of the insulin promoter (73). Simultane-
ous injection of oxidized ATP (oATP) to antagonize of P2X7
in vivo prevented the onset of diabetes (71). As oATP is not an
entirely specific antagonist for P2X7, the implication of other
P2X receptors in this observation cannot be completely ruled out.
Indeed, other ATP-sensitive P2X receptors can also contribute to
purinergic T cell stimulation. For instance, P2X1 and P2X4 were
shown to translocate into the immunological synapse, together
with pannexin 1, following TCR stimulation. In this context, small
molecule antagonists of P2X1 and P2X4 had similar inhibitory
effects on T cell activation as P2X7 antagonists (74). However,
the specificity of some of these small inhibitory molecules is
uncertain, precluding any definitive interpretation of the specific
role of each P2X receptor on T cell stimulation. The generation
of highly specific biological antagonistic nanobodies will certainly
help to gain new insights on their specific roles (75).
Discussion on the Function of P2X7 on
Human and Murine T Cells
Much work in mouse models has led to the conclusion that
P2X7 regulates many aspects of mouse T cell biology. This mul-
tifaceted ATP-gated ion channel is expressed at high levels on
different T cell subsets that are important for the regulation of
immune responses such as Tregs, NKT cells, or Tfh cells. The
question that may be raised is how P2X7 delivers signals that
regulate such distinct events as T cell activation, proliferation,
phenotype, cytokine production, and cell death (Figure 1). A
possible answer might reside in the temporal and spatial regula-
tion of the availability of extracellular purinergic ligands and on
the density of P2X7 expression at the cell surface. Long-lasting
whole-cell activation of P2X7 by high concentrations of ATP or
NAD+ in cells expressing high levels of P2X7 might promote
cell death, whereas short pulses and/or low global amounts of
ATP or its restricted presence at only one side of a cell, such
as would occur in the immunological synapse, might instead
promote TCR-mediated activation of T cells (Figure 3). Hints
in this direction have been provided by studies showing that
low concentrations of ATP co-stimulate proliferation of human
peripheral blood T lymphocytes (76), Jurkat cell (74) and human
activated/memory CD4+ T cells (77), whereas 1mMATP induces
T cell death (76, 77). It may be stressed here that ATP-triggered
cell death of human T cells differs greatly in magnitude and
kinetics as compared to mouse T cells. ATP-triggered cell death
of human T cell is observed in smaller fractions of cells and
only when exposed to millimolar ATP concentrations for a few
days. For comparison, 1–30 µM NAD+ or 100–300 µM of ATP
suffice to induce cell death of the vast majority of mouse T cells
within an hour. These differences may be linked to the lower
expression level of P2X7 at the surface of human T cells and
to the absence of a highly potent T cell-specific P2X7 variant
in humans analogous to the mouse P2X7k variant. Hence, fur-
ther studies will be required to clarify the physiological roles of
P2X7 in the regulation of human T cell death, homeostasis, and
activation.
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